Enhanced immunity effect of Korean Red Ginseng capsule: A randomized, double-blind and placebo-controlled clinical trial

IF 6.8 2区 医学 Q1 CHEMISTRY, MEDICINAL
{"title":"Enhanced immunity effect of Korean Red Ginseng capsule: A randomized, double-blind and placebo-controlled clinical trial","authors":"","doi":"10.1016/j.jgr.2024.05.007","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>As a physiological function of body, immunity can maintain health by identifying itself and excluding others. With economic development and increasingly fierce social competition, the number of sub-healthy population is gradually increasing, and the most basic problem exposed is human hypoimmunity. Hypoimmunity can be manifested as often feeling tired, catching colds, mental depression, etc. In order to enhance immunity, eating healthy foods with the effect of enhancing immunity may become an effective choice. KRG has pharmacological effects of enhancing immunity. Because the screening and evaluation method of immune population are not unified, there are relatively few KRG immunity tests for sub-health population. It is of great significance to study the effect of KRG on people with hypoimmunity to improve sub-health status.</p></div><div><h3>Methods</h3><p>This was a 180-day, randomized, double-blind, placebo-controlled clinical trial. According to the trial scheme design, 119 qualified subjects were included and randomly divided into the test group taking KRG and the placebo control group. Subjects need to check safety indicators (blood pressure and heart rate, blood routine, liver and kidney function, urine routine and stool routine) and efficacy indicators (main and secondary) inspection at baseline, efficacy indicators inspection during the mid-term of the test (90th days of administration), safety and efficacy indicators inspection after the test (180th days of administration).</p></div><div><h3>Results</h3><p>After the test, the safety indicators of placebo control group and KRG test group were basically within the normal range, and there is no significant difference in fireness score between the two groups. Through follow-up interviews, it was found that the subjects in the test group and the control group had no adverse reactions and allergic reactions such as nausea, flatulence, diarrhea, and abdominal pain during the test period. Self-comparison of the test group, the results of the main efficacy indicators: (1) immune related health scores were significantly improved in the mid-term and after the test (<em>P</em> &lt; 0.01), (2) CD3 and CD4/CD8 increased significantly after the test (<em>P</em> &lt; 0.05), (3) IgG, IgA, IgM and WBC increased significantly in the mid-term and after the test (<em>P</em> &lt; 0.01); the results of the secondary efficacy indicators: (1) TNF-α decreased significantly in the mid-term (<em>P</em> &lt; 0.05), IFN-γ decreased significantly in the mid-term (<em>P</em> &lt; 0.01), (2) NK increased significantly in the mid-term and after the test (<em>P</em> &lt; 0.05), (3) monocyte increased significantly in the mid-term and after the test (<em>P</em> &lt; 0.01). Inter-group comparison of the test group and the control group, the results of the main efficacy indicators: (1) immune related health scores were higher than that of the control group in the mid-term and after the test (<em>P</em> &lt; 0.01), (2) IgA of the test group was higher than that of the control group in the mid-term and after the test (<em>P</em> &lt; 0.05); the results of the secondary efficacy indicators: (1) WBC of the test group was higher than that of the control group in the mid-term (<em>P</em> &lt; 0.05); (2) monocytes of the test group were higher than that of the control group in the mid-term and after the test (<em>P</em> &lt; 0.05), neutrophils of the test group were higher than that of the control group in the mid-term (<em>P</em> &lt; 0.05).</p></div><div><h3>Conclusion</h3><p>Taking KRG has no adverse effects on the health of the subjects. According to the standard of clinical trial scheme, the immune related health scores and IgA in the main efficacy indicators were positive, which shows that KRG is helpful in enhancing human immunity.</p></div>","PeriodicalId":16035,"journal":{"name":"Journal of Ginseng Research","volume":null,"pages":null},"PeriodicalIF":6.8000,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1226845324000915/pdfft?md5=fd35f8c1f43b0b07559b7615c13fefdf&pid=1-s2.0-S1226845324000915-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Ginseng Research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1226845324000915","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background

As a physiological function of body, immunity can maintain health by identifying itself and excluding others. With economic development and increasingly fierce social competition, the number of sub-healthy population is gradually increasing, and the most basic problem exposed is human hypoimmunity. Hypoimmunity can be manifested as often feeling tired, catching colds, mental depression, etc. In order to enhance immunity, eating healthy foods with the effect of enhancing immunity may become an effective choice. KRG has pharmacological effects of enhancing immunity. Because the screening and evaluation method of immune population are not unified, there are relatively few KRG immunity tests for sub-health population. It is of great significance to study the effect of KRG on people with hypoimmunity to improve sub-health status.

Methods

This was a 180-day, randomized, double-blind, placebo-controlled clinical trial. According to the trial scheme design, 119 qualified subjects were included and randomly divided into the test group taking KRG and the placebo control group. Subjects need to check safety indicators (blood pressure and heart rate, blood routine, liver and kidney function, urine routine and stool routine) and efficacy indicators (main and secondary) inspection at baseline, efficacy indicators inspection during the mid-term of the test (90th days of administration), safety and efficacy indicators inspection after the test (180th days of administration).

Results

After the test, the safety indicators of placebo control group and KRG test group were basically within the normal range, and there is no significant difference in fireness score between the two groups. Through follow-up interviews, it was found that the subjects in the test group and the control group had no adverse reactions and allergic reactions such as nausea, flatulence, diarrhea, and abdominal pain during the test period. Self-comparison of the test group, the results of the main efficacy indicators: (1) immune related health scores were significantly improved in the mid-term and after the test (P < 0.01), (2) CD3 and CD4/CD8 increased significantly after the test (P < 0.05), (3) IgG, IgA, IgM and WBC increased significantly in the mid-term and after the test (P < 0.01); the results of the secondary efficacy indicators: (1) TNF-α decreased significantly in the mid-term (P < 0.05), IFN-γ decreased significantly in the mid-term (P < 0.01), (2) NK increased significantly in the mid-term and after the test (P < 0.05), (3) monocyte increased significantly in the mid-term and after the test (P < 0.01). Inter-group comparison of the test group and the control group, the results of the main efficacy indicators: (1) immune related health scores were higher than that of the control group in the mid-term and after the test (P < 0.01), (2) IgA of the test group was higher than that of the control group in the mid-term and after the test (P < 0.05); the results of the secondary efficacy indicators: (1) WBC of the test group was higher than that of the control group in the mid-term (P < 0.05); (2) monocytes of the test group were higher than that of the control group in the mid-term and after the test (P < 0.05), neutrophils of the test group were higher than that of the control group in the mid-term (P < 0.05).

Conclusion

Taking KRG has no adverse effects on the health of the subjects. According to the standard of clinical trial scheme, the immune related health scores and IgA in the main efficacy indicators were positive, which shows that KRG is helpful in enhancing human immunity.

Abstract Image

Abstract Image

高丽红参胶囊增强免疫力的作用:随机、双盲和安慰剂对照临床试验
免疫作为人体的一种生理功能,可以通过识别自身、排除他物来维护健康。随着经济的发展和社会竞争的日益激烈,亚健康人群逐渐增多,暴露出的最基本问题就是人体免疫力低下。免疫力低下可表现为经常感到疲劳、感冒、精神不振等。要想增强免疫力,食用具有增强免疫力功效的健康食品不失为一种有效的选择。KRG 具有增强免疫力的药理作用。由于对免疫人群的筛查和评估方法不统一,针对亚健康人群的 KRG 免疫力检测相对较少。研究 KRG 对免疫力低下人群的作用,对改善亚健康状态具有重要意义。这是一项为期 180 天的随机、双盲、安慰剂对照临床试验。根据试验方案设计,119 名合格受试者被随机分为服用 KRG 的试验组和安慰剂对照组。受试者需在基线时进行安全性指标(血压和心率、血常规、肝肾功能、尿常规和大便常规)和疗效指标(主要指标和次要指标)检查,在试验中期(服药第90天)进行疗效指标检查,在试验结束后(服药第180天)进行安全性和疗效指标检查。试验后,安慰剂对照组和 KRG 试验组的安全性指标基本在正常范围内,两组的火热度评分无明显差异。通过随访发现,试验组和对照组受试者在试验期间均未出现恶心、胀气、腹泻、腹痛等不良反应和过敏反应。试验组自我比较,主要疗效指标结果:(1)免疫相关健康评分在试验中期和试验后均明显提高(<0.01),(2)CD3和CD4/CD8在试验后明显提高(<0.05),(3)IgG、IgA、IgM和WBC在试验中期和试验后均明显提高(<0.01);次要疗效指标结果:(1)TNF-α中期明显下降(<0.05),IFN-γ中期明显下降(<0.01);(2)NK中期及试验后明显升高(<0.05);(3)单核细胞中期及试验后明显升高(<0.01)。试验组与对照组组间比较,主要疗效指标结果:(1)试验组免疫相关健康评分在试验中期和试验后均高于对照组(< 0.01),(2)试验组 IgA 在试验中期和试验后均高于对照组(< 0.05);次要疗效指标结果:(1)试验组白细胞在中期高于对照组(<0.05);(2)试验组单核细胞在中期和试验后均高于对照组(<0.05),试验组中性粒细胞在中期高于对照组(<0.05)。服用 KRG 对受试者的健康没有不良影响。根据临床试验方案的标准,免疫相关健康评分和主要疗效指标中的 IgA 均为阳性,这表明 KRG 有助于提高人体免疫力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Ginseng Research
Journal of Ginseng Research CHEMISTRY, MEDICINAL-INTEGRATIVE & COMPLEMENTARY MEDICINE
CiteScore
11.40
自引率
9.50%
发文量
111
审稿时长
6-12 weeks
期刊介绍: Journal of Ginseng Research (JGR) is an official, open access journal of the Korean Society of Ginseng and is the only international journal publishing scholarly reports on ginseng research in the world. The journal is a bimonthly peer-reviewed publication featuring high-quality studies related to basic, pre-clinical, and clinical researches on ginseng to reflect recent progresses in ginseng research. JGR publishes papers, either experimental or theoretical, that advance our understanding of ginseng science, including plant sciences, biology, chemistry, pharmacology, toxicology, pharmacokinetics, veterinary medicine, biochemistry, manufacture, and clinical study of ginseng since 1976. It also includes the new paradigm of integrative research, covering alternative medicinal approaches. Article types considered for publication include review articles, original research articles, and brief reports. JGR helps researchers to understand mechanisms for traditional efficacy of ginseng and to put their clinical evidence together. It provides balanced information on basic science and clinical applications to researchers, manufacturers, practitioners, teachers, scholars, and medical doctors.
文献相关原料
公司名称 产品信息 采购帮参考价格
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信